Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
Artelo Biosciences received a notice of allowance from the Japanese Patent Office for the intended commercial formulation of its lead asset ART27.13, extending patent protection through 2041. This decision aligns with prior allowances in the United States and Europe, securing the IP estate across three major pharmaceutical markets for the peripherally selective dual cannabinoid agonist.
Key figures
- Phase 2 cares dose
- 1300 µg
- Phase 2 dream dose
- 600 µg
- Patent protection until
- 2041
- Phase 2 cares weight gain
- +6%
- Total participants historic
- nearly 300
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.